ITMI20131473A1 - Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale - Google Patents

Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale

Info

Publication number
ITMI20131473A1
ITMI20131473A1 IT001473A ITMI20131473A ITMI20131473A1 IT MI20131473 A1 ITMI20131473 A1 IT MI20131473A1 IT 001473 A IT001473 A IT 001473A IT MI20131473 A ITMI20131473 A IT MI20131473A IT MI20131473 A1 ITMI20131473 A1 IT MI20131473A1
Authority
IT
Italy
Prior art keywords
lactobacillus
microorganisms
composition
placebo
microbiota
Prior art date
Application number
IT001473A
Other languages
English (en)
Italian (it)
Inventor
Andrea Biffi
Walter Fiore
Simone Domenico Guglielmetti
Ruggero Rossi
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sofar Spa filed Critical Sofar Spa
Priority to IT001473A priority Critical patent/ITMI20131473A1/it
Priority to EA202090097A priority patent/EA202090097A1/ru
Priority to EP14790322.3A priority patent/EP3047032A1/en
Priority to HK16112010.3A priority patent/HK1223982A1/zh
Priority to SG11201601664VA priority patent/SG11201601664VA/en
Priority to US14/916,959 priority patent/US20160348155A1/en
Priority to PCT/IB2014/064284 priority patent/WO2015033304A1/en
Priority to JP2016539666A priority patent/JP6701078B2/ja
Priority to EA201690465A priority patent/EA034795B1/ru
Priority to MX2016002766A priority patent/MX2016002766A/es
Priority to BR112016005064A priority patent/BR112016005064A2/pt
Priority to CA2923390A priority patent/CA2923390A1/en
Priority to CN201480049288.XA priority patent/CN105518150A/zh
Publication of ITMI20131473A1 publication Critical patent/ITMI20131473A1/it
Priority to IL244391A priority patent/IL244391B/en
Priority to MX2022013625A priority patent/MX2022013625A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/10—Enterobacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IT001473A 2013-09-06 2013-09-06 Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale ITMI20131473A1 (it)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IT001473A ITMI20131473A1 (it) 2013-09-06 2013-09-06 Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
JP2016539666A JP6701078B2 (ja) 2013-09-06 2014-09-05 微生物を含む組成物の腸内微生物叢に対する効果の評価方法
EA201690465A EA034795B1 (ru) 2013-09-06 2014-09-05 Способ определения изменений фекальной микробиоты индивида после приема композиции, содержащей микроорганизмы
HK16112010.3A HK1223982A1 (zh) 2013-09-06 2014-09-05 用於评价包含微生物的组合物对肠道微生物群的作用的方法
SG11201601664VA SG11201601664VA (en) 2013-09-06 2014-09-05 Method for evaluating the effects of a composition comprising microorganisms on intestinal microbiota
US14/916,959 US20160348155A1 (en) 2013-09-06 2014-09-05 Method for evaluating the effects of a composition comprising microorganisms on intestinal microbiota
PCT/IB2014/064284 WO2015033304A1 (en) 2013-09-06 2014-09-05 Method for evaluating the effects of a composition comprising microorganisms on intestinal microbiota
EA202090097A EA202090097A1 (ru) 2013-09-06 2014-09-05 Способ оценки эффектов композиции, содержащей микроорганизмы, на кишечную микробиоту
EP14790322.3A EP3047032A1 (en) 2013-09-06 2014-09-05 Method for evaluating the effects of a composition comprising microorganisms on intestinal microbiota
MX2016002766A MX2016002766A (es) 2013-09-06 2014-09-05 Metodo para evaluar los efectos de una composicion que comprende microorganismos en la microbiota intestinal.
BR112016005064A BR112016005064A2 (pt) 2013-09-06 2014-09-05 método para avaliar os efeitos de uma composição compreendendo microrganismos em microbiota intestinal
CA2923390A CA2923390A1 (en) 2013-09-06 2014-09-05 Method for evaluating the effects of a composition comprising microorganisms on intestinal microbiota
CN201480049288.XA CN105518150A (zh) 2013-09-06 2014-09-05 用于评价包含微生物的组合物对肠道微生物群的作用的方法
IL244391A IL244391B (en) 2013-09-06 2016-03-02 A method for evaluating the effects of a preparation containing microorganisms on intestinal microbiota
MX2022013625A MX2022013625A (es) 2013-09-06 2016-03-02 Metodo para evaluar los efectos de una composicion que comprende microorganismos en la microbiota intestinal.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001473A ITMI20131473A1 (it) 2013-09-06 2013-09-06 Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale

Publications (1)

Publication Number Publication Date
ITMI20131473A1 true ITMI20131473A1 (it) 2015-03-07

Family

ID=49354801

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001473A ITMI20131473A1 (it) 2013-09-06 2013-09-06 Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale

Country Status (13)

Country Link
US (1) US20160348155A1 (https=)
EP (1) EP3047032A1 (https=)
JP (1) JP6701078B2 (https=)
CN (1) CN105518150A (https=)
BR (1) BR112016005064A2 (https=)
CA (1) CA2923390A1 (https=)
EA (2) EA202090097A1 (https=)
HK (1) HK1223982A1 (https=)
IL (1) IL244391B (https=)
IT (1) ITMI20131473A1 (https=)
MX (2) MX2016002766A (https=)
SG (1) SG11201601664VA (https=)
WO (1) WO2015033304A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
KR102719722B1 (ko) * 2015-10-29 2024-10-18 가부시키가이샤 야쿠르트 혼샤 에쿠올 산생능의 측정 방법
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
CN106318890A (zh) * 2016-10-21 2017-01-11 山东省农业科学院畜牧兽医研究所 一株分离自spf鸡嗉囊的产植酸酶卷曲乳杆菌菌株及其应用
IT201600122724A1 (it) * 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
IT201700101704A1 (it) * 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
MX2020007619A (es) * 2018-01-17 2020-09-28 Consorcio Centro De Investig Biomedica En Red M P Intervenciones dirigidas, encaminadas a reducir los niveles de succinato circulante en un sujeto, y kits y metodo para determinar la eficacia de dichas intervenciones.
CN112384227A (zh) 2018-02-09 2021-02-19 N·V·努特里奇亚 含有不可消化寡糖的发酵配方物
WO2019195342A1 (en) * 2018-04-02 2019-10-10 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
CN110029155A (zh) * 2019-05-27 2019-07-19 天益健康科学研究院（镇江）有限公司 一种基于荧光定量pcr组合式肠道细菌检测方法
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
CN112980712A (zh) * 2019-12-14 2021-06-18 山东大学 一种调节高原人群情绪及肠道菌群稳定的微生物组合物及其应用
CN116287163A (zh) * 2023-02-17 2023-06-23 浙江大学 一种评估肠道菌群对菊粉的动态响应方法
EP4575491A1 (en) 2023-12-22 2025-06-25 Vilnius University Method for detecting volatile organic compounds in faecal matter odour

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022727A1 (en) * 2002-09-06 2004-03-18 Vri Biomedical Ltd Probiotic bacterium: lactobacillus fermentum
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
WO2005001109A2 (en) * 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Methods and compositions to detect microbes in fecal samples
WO2005083122A2 (en) * 2004-02-27 2005-09-09 Stichting Laboratorium Voor Infectieziekten Method for detecting a microorganism in a fecal specimen
WO2006050479A2 (en) * 2004-11-01 2006-05-11 George Mason University Compositions and methods for diagnosing colon disorders
CN1840206A (zh) * 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
WO2007071815A1 (en) * 2005-12-22 2007-06-28 Cyflo Oy Method for monitoring and promoting the nutrition and well-being of an animal and/or a human being as well as the productivity of animals
US20090061446A1 (en) * 2006-02-21 2009-03-05 National University Corporation University Of Toyama Method for quickly identifying pathogenic bacteria responsible for infection
US20100112564A1 (en) * 2008-02-21 2010-05-06 Shanghai Jiao Tong University Methods for detecting therapeutic effects of anti-cancer drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010161944A (ja) * 2009-01-13 2010-07-29 Syngen Biotech Co Ltd 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
WO2004022727A1 (en) * 2002-09-06 2004-03-18 Vri Biomedical Ltd Probiotic bacterium: lactobacillus fermentum
WO2005001109A2 (en) * 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Methods and compositions to detect microbes in fecal samples
WO2005083122A2 (en) * 2004-02-27 2005-09-09 Stichting Laboratorium Voor Infectieziekten Method for detecting a microorganism in a fecal specimen
WO2006050479A2 (en) * 2004-11-01 2006-05-11 George Mason University Compositions and methods for diagnosing colon disorders
WO2007071815A1 (en) * 2005-12-22 2007-06-28 Cyflo Oy Method for monitoring and promoting the nutrition and well-being of an animal and/or a human being as well as the productivity of animals
CN1840206A (zh) * 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
US20090061446A1 (en) * 2006-02-21 2009-03-05 National University Corporation University Of Toyama Method for quickly identifying pathogenic bacteria responsible for infection
US20100112564A1 (en) * 2008-02-21 2010-05-06 Shanghai Jiao Tong University Methods for detecting therapeutic effects of anti-cancer drugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Example Cross-Over Study Design (A Phase II, Randomized, Double-Blind Crossover Study of Hypertena and Placebo in Participants with High Blood Pressure) Methods Study Design", October 2012 (2012-10-01), XP055119522, Retrieved from the Internet <URL:http://prsinfo.clinicaltrials.gov/trainTrainer/Crossover-Design-Fiction-Manuscript.pdf> [retrieved on 20140522] *
F. SAVINO ET AL: "Lactobacillus reuteri DSM 17938 in Infantile Colic: A Randomized, Double-Blind, Placebo-Controlled Trial", PEDIATRICS, vol. 126, no. 3, 16 August 2010 (2010-08-16), pages e526 - e533, XP055119050, ISSN: 0031-4005, DOI: 10.1542/peds.2010-0433 *
PLANT ET AL: "Association of lactobacillus spp. with Peyer's Patches in Mice", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 8, no. 2, 1 January 2001 (2001-01-01), pages 320 - 324, XP002990497, ISSN: 1071-412X, DOI: 10.1128/CDLI.8.2.320-324.2001 *

Also Published As

Publication number Publication date
CN105518150A (zh) 2016-04-20
WO2015033304A1 (en) 2015-03-12
EA034795B1 (ru) 2020-03-23
HK1223982A1 (zh) 2017-08-11
SG11201601664VA (en) 2016-04-28
IL244391B (en) 2021-02-28
IL244391A0 (en) 2016-04-21
EA202090097A1 (ru) 2020-04-07
JP6701078B2 (ja) 2020-05-27
BR112016005064A2 (pt) 2017-11-21
JP2016528926A (ja) 2016-09-23
CA2923390A1 (en) 2015-03-12
EA201690465A1 (ru) 2016-08-31
US20160348155A1 (en) 2016-12-01
MX2022013625A (es) 2022-11-16
EP3047032A1 (en) 2016-07-27
MX2016002766A (es) 2016-08-03

Similar Documents

Publication Publication Date Title
ITMI20131473A1 (it) Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
US11752179B2 (en) Medical use of probiotics
Derrien et al. Fate, activity, and impact of ingested bacteria within the human gut microbiota
ITMI20131467A1 (it) Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
EP3639834B1 (en) Use of microbial communities for human and animal health
Unno et al. Changes in human gut microbiota influenced by probiotic fermented milk ingestion
Rampelli et al. A probiotics-containing biscuit modulates the intestinal microbiota in the elderly
Lebaka et al. Development of new probiotic foods—a case study on probiotic juices
Matijašić et al. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: a randomized double-blind, placebo-controlled trial
Ringel et al. Alterations in the intestinal microbiota and functional bowel symptoms
Gerritsen The genus Romboutsia: genomic and functional characterization of novel bacteria dedicated to life in the intestinal tract
HK1232148A1 (zh) 用於减轻绝经後女性的腹痛的动物双歧杆菌乳酸亚种
EP3870196A1 (en) Bacterial strains of the lactobacillus paracasei species for use, oral or topical, in the treatment of disorders of the female urogenital tract
Matsumoto et al. Dynamics of fecal microbiota in hospitalized elderly fed probiotic LKM512 yogurt
Ghafar et al. Evaluation of the efficacy of probiotics (MCP® BCMC® Strains) treating constipation in elderly patients with multiple chronic co-morbidities: a randomized control trial
Shetty et al. A study to find the status of probiotics in New Delhi, India and review of strains of bacteria used as probiotics
CN118697770A (zh) 副干酪乳酪杆菌207-27在调节情绪方面的用途
WO2019113023A9 (en) Probiotics and methods of use
AU2022228145A1 (en) Method for evaluating the effects of a composition comprising microorganisms on intestinal microbiota
AU2014316687A1 (en) Method for evaluating the effects of a composition comprising microorganisms on intestinal microbiota
Muntingh Ok, so who wants to colonise my gut?-Overview of Probiotics in certain Gastro-intestinal Disorders
HK40101402A (en) New medical use of probiotics
HK40000411A (en) New medical use of probiotics
HK40090429A (zh) 含微生物的组合物增加丁酸、叶酸或烟酸的肠道生产和/或降低琥珀酸的肠道生产的应用